Chemopotentiation by PARP inhibitors in cancer therapy
- 31 July 2005
- journal article
- review article
- Published by Elsevier BV in Pharmacological Research
- Vol. 52 (1), 25-33
- https://doi.org/10.1016/j.phrs.2005.02.010
Abstract
No abstract availableKeywords
Funding Information
- Ministero dell’Istruzione, dell’Università e della Ricerca
This publication has 45 references indexed in Scilit:
- The PARP superfamilyBioEssays, 2004
- MGMT: its role in cancer aetiology and cancer therapeuticsNature Reviews Cancer, 2004
- The biological effects of N3‐methyladenineJournal of Cellular Biochemistry, 2003
- Mediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing FactorScience, 2002
- Poly(ADP-ribose) Polymerase-2 (PARP-2) Is Required for Efficient Base Excision DNA Repair in Association with PARP-1 and XRCC1Journal of Biological Chemistry, 2002
- Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitorsPharmacological Research, 2002
- Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletionProceedings of the National Academy of Sciences of the United States of America, 1999
- Involvement of poly(ADP-ribose) polymerase in base excision repairBiochimie, 1999
- Involvement of the Mismatch Repair System in Temozolomide-Induced ApoptosisMolecular Pharmacology, 1998
- Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trialsCancer Treatment Reviews, 1997